e-learning
resources
Munich 2006
Sunday 03.09.2006
Epidemiology of drug resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The efficiency of polychemotherapy with the use of PAS by the patients with chemoresistant lung tuberculosis
I. B. Byalik, L. M. Tsygankova, V. V. Davidenko (Kiev, Ukraine)
Source:
Annual Congress 2006 - Epidemiology of drug resistant tuberculosis
Session:
Epidemiology of drug resistant tuberculosis
Session type:
E-Posters in free access
Number:
192
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. B. Byalik, L. M. Tsygankova, V. V. Davidenko (Kiev, Ukraine). The efficiency of polychemotherapy with the use of PAS by the patients with chemoresistant lung tuberculosis. Eur Respir J 2006; 28: Suppl. 50, 192
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Second-line treatment patients at relapse of disseminated small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 395s
Year: 2001
Clinical efficacy of once a day linezolid and azithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 690s
Year: 2005
Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
Diaskintest at patients after successful treatment of lung tuberculosis
Source: International Congress 2017 – Migrants and screening
Year: 2017
Clinical characteristic of lung cancer patients with interstitial pneumonia treated with chemotherapy or radiotherapy
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Interstitial lung disease associated by gemcitabine chemotherapy in non-small lung cancer patients: Analysis based on the data in practical use with confirmed denominator
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
The effects of different chemotherapy regimes in the patients with advanced lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 755s
Year: 2006
Effectiveness of chemotherapy in newly detected patients with pulmonary tuberculosis with poly-resistance
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003
Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Combination chemotherapy with gemcitabine using isolated lung perfusion for the treatment of lung metastases
Source: Eur Respir J 2004; 24: Suppl. 48, 42s
Year: 2004
Evaluation of outpatient infections in lung cancer patients treated with chemotherapy and/or radiotherapy
Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer
Year: 2012
Combination therapy of gefitinib and CYP3A4 inhibitor on non-small-cell lung cancer patients with an
EGFR
mutation and carcinomatous meningitis
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept